SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-059674
Filing Date
2024-05-10
Accepted
2024-05-10 09:10:10
Documents
14
Period of Report
2024-05-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2413802d2_8k.htm   iXBRL 8-K 31459
2 EXHIBIT 1.1 tm2413802d2_ex1-1.htm EX-1.1 247164
  Complete submission text file 0001104659-24-059674.txt   516194

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20240510.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20240510_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20240510_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2413802d2_8k_htm.xml XML 3679
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 24933067
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)